Loading data for ALKS — first visit, this takes a few seconds.
Alkermes plc (ALKS)
NasdaqGS: ALKS
· Real-Time Price · USD
47.20
+0.21 (0.45%)
At close: Sep 01, 2026, 8:00 PM
47.20
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Alkermes plc (ALKS) Stock Price, Analysis & Data
No data available
| Bid | 39.86 |
| Market Cap | 7.92B |
| Revenue (ttm) | 1.67B |
| Net Income (ttm) | 66.1M |
| 0.27 | |
| 0.38 | |
| 124.21 | |
| 25.82 | |
| P/B (ttm) | 4.37 |
| P/S (ttm) | 4.75 |
| Earnings Date | Oct 28, 2026 |
| Ask | 53.36 |
| Volume | 1,191,259 |
| Avg. Volume (20D) | 1,960,512 |
| Open | 47.00 |
| Previous Close | 46.99 |
| Day's Range | 46.67 - 47.34 |
| 52-Week Range | 25.17 - 55.67 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product cand...
Sector Healthcare
IPO Date Jul 16, 1991
Employees 2,050
Stock Exchange NasdaqGS
Ticker Symbol ALKS
Website https://www.alkermes.com
Financial Performance
In 2025, Alkermes plc's revenue was 1.48B, a decrease of -5.25% compared to the previous year's 1.56B. Earnings were 241.66M, a decrease of -34.16%.
Financial StatementsEarnings Surprise
Alkermes plc has released their quarterly earnings on Jul 28, 2026:
- Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
- EPS of 0.7 exceeds estimates by 0.41, with 2.94% YoY growth.
Alkermes plc is scheduled to release its earnings on Oct 28, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2